Acyl Dipeptides as reversible caspase inhibitors. Part 2: Further optimization

被引：19
|
作者：
Linton, SD
Karanewsky, DS
Ternansky, RJ
Chen, N
Guo, M
Jahangiri, KG
Kalish, VJ
Meduna, SP
Robinson, ED
Ullman, BR
Wu, JC
Pham, B
Kodandapani, L
Smidt, R
Diaz, JL
Fritz, LC
von Krosigk, U
Roggo, S
Schmitz, A
Tomaselli, KJ
机构：
[1] Idun Pharmaceut Inc, San Diego, CA 92121 USA
[2] Novartis Pharma Ltd, Pharma Res, CH-4002 Basel, Switzerland
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2002年 / 12卷 / 20期
关键词：
D O I：
10.1016/S0960-894X(02)00630-3
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A new structural class of broad spectrum caspase inhibitors was optimized for its activity against caspases 1, 3, 6, 7, and 8. The most potent compound had low nanomolar broad spectrum activity, in particular, single digit nanomolar inhibitory activity against caspase 8. (C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码：2973 / 2975
页数：3
相关论文
共 50 条
  • [1] Acyl Dipeptides as reversible caspase inhibitors. Part 1: Initial lead optimization
    Linton, SD
    Karanewsky, DS
    Ternansky, RJ
    Wu, JC
    Pham, B
    Kodandapani, L
    Smidt, R
    Diaz, JL
    Fritz, LC
    Tomaselli, KJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (20) : 2969 - 2971
  • [2] Structure-activity relationships within a series of caspase inhibitors. Part 2: Heterocyclic warheads
    Ullman, BR
    Aja, T
    Chen, N
    Diaz, JL
    Gu, X
    Herrmann, J
    Kalish, VJ
    Karanewsky, DS
    Kodandapani, L
    Krebs, JJ
    Linton, SD
    Meduna, SP
    Nalley, K
    Robinson, ED
    Roggo, SP
    Sayers, RO
    Schmitz, A
    Ternansky, RJ
    Tomaselli, KJ
    Wu, JC
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (15) : 3632 - 3636
  • [3] Orally active thrombin inhibitors.: Part 2:: Optimization of the P2-moiety
    Lange, UEW
    Baucke, D
    Hornberger, W
    Mack, H
    Seitz, W
    Höffken, HW
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) : 2648 - 2653
  • [4] Indole RSK inhibitors. Part 2: Optimization of cell potency and kinase selectivity
    Kirrane, Thomas M.
    Boyer, Stephen J.
    Burke, Jennifer
    Guo, Xin
    Snow, Roger J.
    Soleymanzadeh, Lida
    Swinamer, Alan
    Zhang, Yunlong
    Madwed, Jeffery B.
    Kashem, Mohammed
    Kugler, Stanley
    O'Neill, Margaret M.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, 22 (01) : 738 - 742
  • [5] The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: Lead optimization
    Siu, Tony
    Kumarasinghe, Sathyajith E.
    Altman, Michael D.
    Katcher, Matthew
    Northrup, Alan
    White, Catherine
    Rosenstein, Craig
    Mathur, Anjili
    Xu, Lin
    Chan, Grace
    Bachman, Eric
    Bouthillette, Melaney
    Dinsmore, Christopher J.
    Marshall, C. Gary
    Young, Jonathan R.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (06) : 1466 - 1471
  • [6] Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties
    Hartung, Ingo V.
    Hammer, Stefanie
    Hitchcock, Marion
    Neuhaus, Roland
    Scholz, Arne
    Siemeister, Gerhard
    Bohlmann, Rolf
    Hillig, Roman C.
    Puehler, Florian
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (01) : 186 - 193
  • [7] Respiratory syncytial virus fusion inhibitors. Part 4: Optimization for oral bioavailability
    Yu, Kuo-Long
    Sin, Ny
    Civiello, Rita L.
    Wang, X. Alan
    Combrink, Keith D.
    Gulgeze, H. Belgin
    Venables, Brian L.
    Wright, J. J. Kim
    Dalterio, Richard A.
    Zadjura, Lisa
    Marino, Anthony
    Dando, Sandra
    D'Arienzo, Celia
    Kadow, Kathleen F.
    Cianci, Christopher W.
    Li, Zhufang
    Clarke, Junius
    Genovesi, Eugene V.
    Medina, Ivette
    Lamb, Lucinda
    Colonno, Richard J.
    Yang, Zheng
    Krystal, Mark
    Meanwell, Nicholas A.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (04) : 895 - 901
  • [8] Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories
    Hartung, Ingo V.
    Hitchcock, Marion
    Puehler, Florian
    Neuhaus, Roland
    Scholz, Arne
    Hammer, Stefanie
    Petersen, Kirstin
    Siemeister, Gerhard
    Brittain, Dominic
    Hillig, Roman C.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (08) : 2384 - 2390
  • [9] 2,4-Diaminopyrimidine MK2 inhibitors. Part II: Structure-based inhibitor optimization
    Harris, Christopher M.
    Ericsson, Anna M.
    Argiriadi, Maria A.
    Barberis, Claude
    Borhani, David W.
    Burchat, Andrew
    Calderwood, David J.
    Cunha, George A.
    Dixon, Richard W.
    Frank, Kristine E.
    Johnson, Eric F.
    Kamens, Joanne
    Kwak, Silvia
    Li, Biqin
    Mullen, Kelly D.
    Perron, Denise C.
    Wang, Lu
    Wishart, Neil
    Wu, Xiaoyun
    Zhang, Xiaolei
    Zmetra, Tami R.
    Talanian, Robert V.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (01) : 334 - 337
  • [10] Orally active thrombin inhibitors.: Part 1:: Optimization of the P1-moiety
    Mack, H
    Baucke, D
    Hornberger, W
    Lange, UEW
    Seitz, W
    Höffken, HW
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2006, 16 (10) : 2641 - 2647
12345